AiCure and OncoBay Clinical have announced a partnership to provide oncology sponsors with scalable, AI-powered insights. A subsidiary of the Moffitt Cancer Center, OncoBay will make AiCure's proprietary AI platform available for oncology trials, aiming to provide sponsors and sites with a more holistic understanding of patient health and site optimization.
The oncology drug pipeline has grown by 63% since 2013, but the average success rate of oncology drugs is only 3.4%. To address this discrepancy and the unique challenges of oncology trials, particularly given the complex treatment regimens, AiCure and OncoBay aim to improve patient support and trial retention, while also providing sponsors and sites with greater visibility into patient behavior. Through AiCure's patient engagement solution, Patient Connect, oncology sites can remotely monitor patients and use real-time communication tools to guide them through treatment protocols, including which medication to take and when, as well as allow direct access to a clinician.
To learn more, click
